semaglutide cmpd Diabetes Drug Could Help Reduce Risk for Cardiovascular Events, Study Finds RemedyMeds

Two additional ziltivekimab studies examining cardiovascular outcomes remain under way, with results expected during the first half of next year

Understanding both your medication's stability window and your personalized genetic profile enables more informed conversations with your provider about supply planning, dosing cadence, and treatment continuity

Stimulant laxatives, such as Dulcolax, senna/sennosides, and Senokot (Bisacodyl)

Best JH, Boye KS, Rubin RR, Cao D, Kim TH, Peyrot M

Future evidence may highlight specific populations, not yet covered by guidance, who may benefit from taking them. For food and beverage, this will create challenges as well as opportunities but staying across the science is essential for exploiting them